BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 8, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2018

View Archived Issues

Researchers present gene therapy for methamphetamine-induced inflammation

Read More

Patient recruitment ongoing in phase II/III trial of relatlimab plus nivolumab in melanoma

Read More

Duke University patents mitochondrial antiviral-signaling protein compositions

Read More

Orion Pharma enrolls participants in first-in-human study of ODM-208

Read More

Achaogen receives funds to support development of aminoglycoside antibiotics

Read More

Positive outcome of interim analysis of STRIDE-1 study of AXS-05

Read More

Asavi presents inhibitors of HCV NS5B polymerase, HBV DNA polimerase and HIV-1 reverse transcriptase

Read More

Novel STAT5 inhibitors synthesized at Freie Universitaet Berlin

Read More

AbbVie, Galapagos discover new CFTR modulators

Read More

Oppilotech awarded grant for bacterial cell wall model

Read More

U.S. Department of Health & Human Services, Codagenix patent novel RSV vaccine

Read More

Amgen profiles pipeline progress of first quarter 2018

Read More

Venglustat shows favorable safety and tolerability and biologic activity in healthy volunteers

Read More

New phase II trial studies ISA-101 with utomilumab for HPV16-positive oropharyngeal cancer

Read More

FDA grants breakthrough therapy designation to OMS-721 for HSCT thrombotic microangiopathy

Read More

Vertex initiates phase III studies of VX-445, tezacaftor and ivacaftor in cystic fibrosis

Read More

DNAJC15 expression linked to NAFLD pathogenesis

Read More

Onxeo initiates phase I study of intravenous AsiDNA in advanced solid cancers

Read More

Neuraltus' NP-001 safe and well tolerated but does not slow disease progression in ALS

Read More

Lupus Research Alliance collaborates with Bristol-Myers Squibb to study BMS-986165 for lupus

Read More

ThromboGenics initiates phase II trial of THR-317 with Lucentis for DME

Read More

Proteus Digital Health expands digital medicine pipeline into oncology

Read More

Fujirebio, Janssen enter agreement to develop amyloid beta 42/40 ratio assay

Read More

Tusk Therapeutics' TSK-011010 described as best-in-class anti-CD38 antibody

Read More

MSD applies to expand approval of Keytruda in Japan

Read More

ZED-1227 begins phase IIa study in patients with celiac disease

Read More

Bristol-Myers Squibb updates key milestones of first quarter 2018

Read More

Ono files for Japanese approval of metyrosine for patients with pheochromocytoma

Read More

Chugai files in Japan for Hemlibra for hemophilia A without inhibitors and to extend dosing interval

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing